The National Hemophilia Foundation’s (NHF's) Medical and Scientific Advisory Council (MASAC) issued the following new documents, which were adopted by NHF’s Board of Directors in June 2015:

MASAC Document #232 was created in direct response to an NHF-hosted von Willebrand disease (VWD) Summit. The purpose of the summit was to identify, through vigorous discussion, gaps in care for individuals with VWD. MASAC produced a document that both summarizes the discussion highlights and provides subsequent recommendations that seek to address the healthcare needs of an underserved US VWD population. View and download MASAC Recommendations on the Care and Treatment of Individuals with von Willebrand Disease.

MASAC Document #233 covers the safe and effective at-home use of bypassing agents in patients with hemophilia A or B and inhibitors. The recommendations within the document stress the importance of education and information relevant to factor administration, symptom identification and emergency response. View and download MASAC Recommendation on Administration of Inhibitor Bypassing Agents in the Home for Patients with Hemophilia and Inhibitors.

MASAC Document #234 encompasses recommendations relevant to the testing, assessment and treatment of hepatitis C viral (HCV) infection in people with bleeding disorders. The document also includes a recommendation concerning reimbursement for, and access to, newer and more effective HCV drugs. View and download MASAC Recommendations on Treatment of Hepatitis C in Individuals with Hemophilia and Other Bleeding Disorders.

MASAC Document #235 includes the council’s most recent series of treatment recommendations, including information on currently available therapies. View and download MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders.

Click here to view the complete list of current MASAC documents. To request a hard copy of any current documents, please contact HANDI, NHF’s information resource center: handi@hemophilia.org or 1.800.424.2634.